Combination Treatment with Hepatitis C Virus Protease and NS5A Inhibitors Is Effective against Recombinant Genotype 1a, 2a, and 3a Viruses

With the development of directly acting antivirals, hepatitis C virus (HCV) therapy entered a new era. However, rapid selection of resistance mutations necessitates combination therapy. To study combination therapy in infectious culture systems, we aimed at developing HCV semi-full-length (semi-FL)...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Gottwein, Judith M., Jensen, Sanne B., Li, Yi-Ping, Ghanem, Lubna, Scheel, Troels K. H., Serre, Stéphanie B. N., Mikkelsen, Lotte, Bukh, Jens
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Microbiology 2013
Assuntos:
Antiviral Agents
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3591891/
https://ncbi.nlm.nih.gov/pubmed/23274664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02164-12
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares